A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 559 participants.
Also called NCT05971940
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 559 participants
- Sponsor
- Registry
-
NCT05971940
-
- Other papers using this trial's data
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, China, India, Japan, Mexico, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT05971940. Randomized; double masking; primary purpose treatment. Start 2023-08-09 (actual); primary completion 2025-04-03 (actual). Results posted on 2026-04-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
- Acronym
- ACHIEVE-1
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05971940- Content hash
e113b25c29fa6f990b1ecc1d8d86e02a0af4cfc9051efab6b60154da354bd25b